Sandra and Edward Meyer Cancer Center

A powerful new set of scientific tools developed by Weill Cornell Medicine and New York Genome Center (NYGC) researchers enables them to track the molecular evolution of cancers. 

The work of global oncologists – whose insights and innovations reduce the burden of cancer around the world – has demonstrated value that academic medical leadership should consider when assessing these physicians for professional advancement, according to a commentary by Weill Cornell Medicine investigators.

Weill Cornell Medicine has experienced dynamic growth in its research enterprise over the past five years, an achievement that underscores the institution’s mission to provide patients with the most advanced treatments and therapies.

Long-term spaceflight causes more changes to gene expression than shorter trips, especially to the immune system and DNA repair systems, according to research by Weill Cornell Medicine and NASA investigators as part of NASA’s Twins Study, which followed the only set of identical twin astronauts for more than two years.  

The deletion of a gene that normally promotes healthy cell division in the prostate encourages the growth of cancer in the gland, according to a new study by Weill Cornell Medicine investigators. The findings, published March 28 in Cancer Cell, suggest that the gene, once deleted, helps to promote tumorous growth.

A drug already approved for anemia offers hope for people leukemia.

Consuming the equivalent of one can of soda per day caused mice predisposed to colon cancer to develop larger tumors, according to a study by Weill Cornell Medicine and NewYork-Presbyterian investigators.

Biochemist Dr. Lewis Cantley is finding increasing evidence of a strong connection between sugar and cancer.

Dr. Manuel Hidalgo, a leading physician-scientist who specializes in pancreatic cancer and drug development, has been named chief of the Division of Hematology and Medical Oncology in the Weill Department of Medicine at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center, effective June 1. 

Treating patients with advanced, metastatic esophageal cancer with an immune-system boosting drug called pembrolizumab, known by its brand name Keytruda, led to regression of tumors in some patients, according to results of a phase 2 clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators.

New studies from Weill Cornell Medicine researchers have revealed the importance of two gene-regulation proteins in the development of common immune cell cancers called lymphomas.

Researchers at Weill Cornell Medicine, in collaboration with investigators at Dana-Farber Cancer Institute, have been awarded a three-year, $1 million grant from the U.S. Department of Defense (DoD) for prostate cancer clinical trials.

Seven Weill Cornell Medicine faculty members leading multi-institutional research teams were awarded grants from The Starr Foundation's 12th Starr Cancer Consortium Grant Competition to fund their innovative cancer research projects.

Postmenopausal women with higher levels of body fat have a significantly increased risk of developing breast cancer even if they have a normal body mass index (BMI), according to a new study.

A study of the dual pathways that process the essential vitamin folate by Weill Cornell Medicine investigators unexpectedly revealed a new way the cancer drug methotrexate works and may suggest strategies to boost its cancer-killing effects.

Dr. Massimo Loda Appointed Chair of the Department of Pathology and Laboratory Medicine at Weill Cornell Medicine and Pathologist-in-Chief at NewYork-Presbyterian/Weill Cornell Medical Center

Weill Cornell Medicine investigators Dr. David Lyden and Dr. Ari Melnick have been awarded Outstanding Investigator Awards from the National Cancer Institute.

Ovarian tumors disable the immune system’s killer T cells—which protect the body by destroying infected or malignant cells—enabling the disease to flourish unchecked, according to a new study by Weill Cornell Medicine scientists.

Dr. Dan Landau has received a New Innovator Award from the National Institutes of Health for his research on how tumor cells evolve and acquire new mutations to evade cancer therapies.

A very low carbohydrate, high-fat diet called the ketogenic diet may improve the effectiveness of an emerging class of cancer drugs, according to a study in mice by investigators at Weill Cornell Medicine, Columbia University Irving Medical Center and NewYork-Presbyterian.